PhaseRx Inc (NASDAQ:PZRX) Updates On Orphan Drug Designation For PRX-ASL

PhaseRx Inc (NASDAQ:PZRX) reported that the European Medicines Agency’s COMP has given a positive view recommending orphan medicinal product status for PRX-ASL, for the cure of argininosuccinate lyase deficiency, the company’s second drug candidate to cure a urea cycle disorder. The details ASLD can be stated as a rare liver disorder, which is a result […]